Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
31 oct. 2024 08h00 HE
|
Mangoceuticals, Inc.
Dallas, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness...
MangoRx Announces Formation of Strategy and Alternatives Committee
22 oct. 2024 08h00 HE
|
Mangoceuticals, Inc.
Dallas, Texas, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness...
MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly
21 oct. 2024 17h10 HE
|
Mangoceuticals, Inc.
Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness...
MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN
11 oct. 2024 17h15 HE
|
Mangoceuticals, Inc.
DALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and...
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
03 oct. 2024 08h30 HE
|
Mangoceuticals, Inc.
Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness...
MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment
01 oct. 2024 07h30 HE
|
Mangoceuticals, Inc.
MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss category Dallas, Texas, Oct. 01, 2024 (GLOBE NEWSWIRE) --...
MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024
15 août 2024 09h25 HE
|
Mangoceuticals, Inc.
Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
MangoRx Receives Certificate of Grant in India for its Respiratory Illness and Preventive Care Technology Patent
13 août 2024 16h00 HE
|
Mangoceuticals, Inc.
Dallas, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
09 août 2024 08h15 HE
|
Mangoceuticals, Inc.
Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology
24 juil. 2024 08h15 HE
|
Mangoceuticals, Inc.
Dallas, Texas, July 24, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a leader in men’s health and wellness products including erectile dysfunction (ED),...